A Retrospective Clinical Comparison of Two Allogeneic Bone Matrices Containing Viable Osteogenic Cells in Patients Undergoing Foot and/or Ankle Arthrodesis

Loveland, Jeff D; Waldorff, Erik I.; He, Donghong; Atkinson, Brent L.

doi:10.4172/2157-7633.1000405

Cited by 5 publications

(3 citation statements)

References 36 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VBA patients also reported significantly greater improvement in pain scores and overall satisfaction. Other recent literature also reports a lower rate of fusion in foot and ankle procedures with MSC-based CBAs, from 68 to 79% (Jones et al 2015 ; Loveland et al 2017 ). Similarly, reported fusion rates in the spine are generally lower with MSC-based CBAs (68 to 87%; McAnany et al 2016 ; Overley et al 2019 ) than those with VBA (92 to 98%; Elgafy et al 2021 ; Hall et al 2019 ).…”

Section: Discussionmentioning

confidence: 96%

Characterization of an advanced viable bone allograft with preserved native bone-forming cells

et al. 2022

View full text Add to dashboard Cite

Bone grafts are widely used to successfully restore structure and function to patients with a broad range of musculoskeletal ailments and bone defects. Autogenous bone grafts are historically preferred because they theoretically contain the three essential components of bone healing (ie, osteoconductivity, osteoinductivity, and osteogenicity), but they have inherent limitations. Allograft bone derived from deceased human donors is one alternative that is also capable of providing both an osteoconductive scaffold and osteoinductive potential but, until recently, lacked the osteogenic component of bone healing. Relatively new, cellular bone allografts (CBAs) were designed to address this need by preserving viable cells. Although most commercially-available CBAs feature mesenchymal stem cells (MSCs), osteogenic differentiation is time-consuming and complex. A more advanced graft, a viable bone allograft (VBA), was thus developed to preserve lineage-committed bone-forming cells, which may be more suitable than MSCs to promote bone fusion. The purpose of this paper was to present the results of preclinical research characterizing VBA. Through a comprehensive series of in vitro and in vivo assays, the present results demonstrate that VBA in its final form is capable of providing all three essential bone remodeling properties and contains viable lineage-committed bone-forming cells, which do not elicit an immune response. The results are discussed in the context of clinical evidence published to date that further supports VBA as a potential alternative to autograft without the associated drawbacks.

show abstract

Section: Discussionmentioning

confidence: 96%

Characterization of an advanced viable bone allograft with preserved native bone-forming cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Allografts may be more readily available; however, the drawbacks of allografts include the risk of disease transmission, potential antigenic response, nonuniform preservation practices, potential structural weaknesses, cost, and possible increased risk of nonunion or failure (13,14,15). bioactive nanoparticles that can stimulate bone tissue formation (16,17,18,19,20).…”

Section: Discussionmentioning

confidence: 99%

A Multicenter, Retrospective, Case Series of Patients With Charcot Neuroarthropathy Deformities Undergoing Arthrodesis Utilizing Recombinant Human Platelet-derived Growth Factor With Beta-Tricalcium Phosphate

Loveland

McMillen

Cala

2021

The Journal of Foot and Ankle Surgery

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Cell death and apoptosis do not seem to harbor biopotential although the full understanding remains to be elucidated. While some clinical success of allogeneic cellular bone grafts has been reported, cytotoxicity effects may be present which need to be overcome and may depend in part on the osteogenic capacity of the patient to do so [23–28]. One review of cryopreservation studies reported that while mesenchymal stromal cells (MSCs) “have proved amenable to cryopreservation by conventional slow cooling protocols, their pluripotent counterparts have been shown to be more refractory” [16].…”

Section: Dmso Cytotoxicitymentioning

confidence: 99%

Methods of Cryoprotectant Preservation: Allogeneic Cellular Bone Grafts and Potential Effects

Martin

Sicard

Namin

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Debridement of the bone surface during a surgical fusion procedure initiates an injury response promoting a healing cascade of molecular mediators released over time. Autologous grafts offer natural scaffolding to fill the bone void and to provide local bone cells. Commercial bone grafting products such as allografts, synthetic bone mineral products, etc., are used to supplement or to replace autologous grafts by supporting osteoinductivity, osteoconductivity, and osteogenesis at the surgical site. To assure osteogenic potential, preservation of allogeneic cells with cryoprotectants has been developed to allow for long-term storage and thus delivery of viable bone cells to the surgical site. Dimethyl sulfoxide (DMSO) is an intracellular cryoprotectant commonly used because it provides good viability of the cells post-thaw. However, there is known cytotoxicity reported for DMSO when cells are stored above cryogenic temperatures. For most cellular bone graft products, the cryoprotectant is incorporated with the cells into the other mineralized bone and demineralized bone components. During thawing, the DMSO may not be sufficiently removed from allograft products compared to its use in a cell suspension where removal by washing and centrifugation is available. Therefore, both the allogeneic cell types in the bone grafting product and the local cell types at the bone grafting site could be affected as cytotoxicity varies by cell type and by DMSO content according to reported studies. Overcoming cytotoxicity may be an additional challenge in the formation of bone at a wound or surgical site. Other extracellular cryoprotectants have been explored as alternatives to DMSO which preserve without entering the cell membrane, thereby providing good cellular viability post-thaw and might abrogate the cytotoxicity concerns.

show abstract

A Retrospective Clinical Comparison of Two Allogeneic Bone Matrices Containing Viable Osteogenic Cells in Patients Undergoing Foot and/or Ankle Arthrodesis

Cited by 5 publications

References 36 publications

Characterization of an advanced viable bone allograft with preserved native bone-forming cells

Characterization of an advanced viable bone allograft with preserved native bone-forming cells

A Multicenter, Retrospective, Case Series of Patients With Charcot Neuroarthropathy Deformities Undergoing Arthrodesis Utilizing Recombinant Human Platelet-derived Growth Factor With Beta-Tricalcium Phosphate

Methods of Cryoprotectant Preservation: Allogeneic Cellular Bone Grafts and Potential Effects

Contact Info

Product

Resources

About